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EDITORIAL
Do patients with COPD benefit from treatment 
with inhaled corticosteroids?
C.P. van Schayck*, P.M. van Grunsven, P.N.R. Dekhuijzen
In the past few years, treatment with inhaled cortico­
steroids has become increasingly important in asthma [1, 
2]. It appears that inflammation of the airway wall is a 
major pathophysiological mechanism underlying asthma
[3], and perhaps also chronic obstructive pulmonary dis­
ease (COPD) [4]. Some long-term studies in asthmatic 
patients over 1 and 2 yrs have shown that maintenance 
treatment with inhaled corticosteroids is beneficial [5-  
7]. In contrast to asthma, the efficacy and therefore the 
precise role of inhaled corticosteroids is less clear in the 
treatment of patients with COPD [8, 9]. Corticosteroids 
are generally given in COPD, in order to treat exacer­
bations, for a relatively short period of time. The effi­
cacy of long-term treatment with inhaled steroids is not 
yet established. Whilst in asthma the response is rapid, 
there are indications that (some) patients with COPD 
may only respond adequately to (oral) corticosteroids 
after 6 months to 2 yrs of therapy [10]. We have, there­
fore, investigated the literature over the past 15 yrs on 
short-term as well as long-term response to inhaled ste­
roids in COPD. This was done by means of a Medline 
Search (MeSH headings and/or free text words: anti- 
inflammatory-agents-steroidal; chronic airflow obstruc­
tion; COPD-chronic obstructive pulmonary disease). Only 
randomized controlled studies (English-written) with 
inhaled steroids were included. Special attention was 
paid to possible predictors of a long-term response to 
inhaled steroids in COPD.
Effects of inhaled steroids in COPD
Of the 103 studies found in Medline, only 14 matched 
the inclusion criteria. Most of these studies were short­
term studies, ranging from 2 weeks to 3 months [11-20]. 
Only a few long-term prospective studies with inhaled 
corticosteroids in COPD were available, ranging 12-30 
months [21-24], of which one study [22] was the (24 
month) follow-up of a 12 month study [21]. The other 
long-term study [23] did not make a distinction between 
asthma and COPD but studied post-hoc a group with a 
symptom-based diagnosis of COPD. There was one other 
study published in abstract form only, of long-term con­
trolled use of inhaled steroids in COPD [25].
Table 1 presents an overview of the design and results 
of these studies. Most short-term studies show that inha­
led steroids have beneficial effects on lung function (for­
ced expiratory volume in one second (FEVl), forced vital
* Correspondence: C.P. van Schayck, Dept of General Practice, Nijmegen 
University, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
capacity (FVC) and peak expiratory flow rate (PEFR)) 
when given in dosages of 1,500-3,000 jjg beclometha- 
sone daily for 2-6 weeks [11-17]. When compared with 
oral steroids, the effects of inhaled steroids on lung func­
tion were less pronounced [11-15]. Lower dosages of 
budesonide (800-1,600 ^g) for 8 weeks to 3 months did 
not result in a significant improvement in lung function 
[18-20], None of these studies showed any effect on 
bronchial hyperresponsiveness as assessed by the pro­
vocative concentration of agonist producing a 20% fall 
in FEVl (PC20), although high doses of beclomethasone 
may have some effect on the inflammation assessed by 
means of bronchoalveolar lavage (BAL) [17]. Two stud­
ies showed small effects on one specific symptom (dys­
pnoea and cough) but not on symptom scores in general
[18, 19].
Long-term studies with 800-1,600 pg beclomethasone 
or budesonide for 12-30 months [21-25] generally sho­
wed the same tendency: small improvements in lung 
function (FEVl, FVC and PEFR), but no change in bron­
chial hyperresponsiveness (PC20). During inhaled steroid 
usage, symptoms decreased to a small extent [22, 24], 
and there was a small reduction in the number of exac­
erbations [22, 23] or the days of oral steroid use during 
exacerbations [25]. As could be expected, the treatment 
benefits of inhaled corticosteroids were much more pro­
nounced in patients with asthma than in those with 
COPD [21-23]. In asthma, inhaled steroids not only 
markedly improved the level of lung function and bron­
chial hyperresponsiveness, but also the yearly decline in 
lung function (the progression of the disease) to a far 
greater extent than in COPD. For instance, in one study
[22], the average increase in FEVl during steroid ther­
apy in COPD was 0.098 L, which was only 43% of the 
0.228 L increase in asthma. In the same study, the PC20 
decreased by 3.2 doubling doses in COPD, whereas in 
patients with asthma an increase of 2.1 doubling doses 
was found during the same period (p<0.05).
Predictors of a long-term response to 
inhaled steroids in COPD
So far, there has only been one study investigating the 
predictors of a long-term response to inhaled steroids
[23]. Within a group of 91 patients, treated with beclome­
thasone 800 fig daily for 30 months, it was shown that 
subjects who did not smoke, who had allergies, or who 
were less than 40 yrs of age benefited more from their 
treatment (improvement in lung function) than did those 
who smoked, did not have allergies, or were over 40 yrs 
of age. A further analysis of this study showed that the
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Table 1. -  Summary of studies published so far concerning the effect of inhaled steroids in COPD
[Ref,] Pts
n
Therapy
pgday-1
Design Drop-outs
Short-term studies
[11] 12 Beclomethasone Double-blind/" cross-over" -
1,600, 2 weeks comparison
[12] 83 Beclomethasone Double-blind/" cross-over" -
1,500, 2 weeks comparison
[13, 14] 127 Beclomethasone Double-blind/"cross-over" -
1,500, 2 weeks comparison
[15] 107 Beclomethasone Double-blind/” cross-over" -
1,500, 2 weeks comparison
[16] 105 Beclomethasone Double-blind/" parallel"
l,500v^ 3,000, comparison
3 weeks
[17] 30 Beclomethasone Double-blind/"parallel" -
2,000, 6 weeks comparison
[18] 24 Budesonide Double-blind/" parallel" 3
1,600, 8 weeks comparison
m 25 Budesonide Double-blind/'1 p arallel" 7
800, 12 weeks comparison
[20] 14 Budesonide Double-blind/" cross-over" -
1,200, 3 months comparison
Long-term studies
[21, 22] 28 Beclomethasone Single-blind/" wi thin-patient" 6
800, 12/24 months comparison
[23] 39/2741- Beclomethasone Double-blind/''parallel” 12 in steroid
800, 30 months comparison group versus
44 in control
group
[24] 58 Budesonide Double-blind/"parallel" 2/40 in steroid
1,600, 24 months comparison versus 5/18 in
control group
[25]# 194 Beclomethasone Double-blind/"paraller 24
1,500, 24 months comparison
Results
FEVl T, but less than with prednisone 
FEVi, FVC and PEFR T, but less than with
prednisolone
FEVi, FVC and PEFR T, but less than with 
prednisolone
FEVi, FVC and PEFR T, but less effective 
than prednisone in emphysema 
FEVl, FVC and PEFR t ,  no difference 
between 1,500 versus 3,000 jag; PC20 no 
change; QOL T
FEVl, FVC T; inflammation (BAL) I
FEVl, FVC, PEFR, rescue medication 
and PC20 no change; symptoms (only 
dyspnoea) i?
FEVi, FVC and PC20 no change; symptoms 
(only cough) I
FEVl, FVC and PC20 no change
FEVl, FVC and PEFR T; PC20 no change; 
symptoms, exacerbations (only during 24 
months [22]) and diurnal variation PEFR I  
FEVl, T; exacerbations i ;  PC20 no changet
Symptoms decreased; FEVl and 
exacerbations a nonsignificant improvement
FEVl and PEFR T; less oral steroid days 
(during exacerbations)
■ PHfrw
t: 39 subjects out of 274 had a symptom-based diagnosis of COPD, drop-outs are given for the total group of 274 patients, results 
only for the 39 COPD patients; published only in abstract form. COPD: chronic obstructive pulmonary disease; [Ref.]: refer­
ence number; Pts: patients; FEVl: forced expiratory volume in one second; FVC: forced vital capacity; PEFR: peak expiratory 
flow rate; PC20: provocative dose of agonist producing a 20% fall in FEVl; QOL: quality of life; BAL: bronchoalveolar lavage; 
T: increased; X: decreased.
bronchodilator response, PC20, total immunoglobulin E 
(IgE) and smoking habits were all independent predic­
tors of the treatment response to inhaled steroids [26], 
As already mentioned, a problem in this study was that 
no distinction was made between asthma and COPD, and 
the inclusion criteria of this study (increased hyperre­
sponsiveness and reversibility of obstruction) tended to 
select more asthmatics than patients with COPD. There­
fore, on the basis of this study, no firm conclusion can 
be drawn about predictors of a long-term response to 
inhaled steroids in COPD. We have, therefore, analy­
sed the data from our study [22], in order to investigate 
which subgroups of patients with COPD respond most 
to inhaled corticosteroids [27]. Our hypothesis was that 
COPD patients with more asthmatic features would bene­
fit most from long-term treatment with inhaled steroids. 
The improvement in FEVl during steroid treatment ap­
peared to be greater in patients with more airway ob­
struction (as assessed by the FEVi/vital capacity (VC)), 
a higher reversibility of this obstruction, and a larger dec­
line in FEVl before steroid therapy. Current smokers and 
smokers with more pack-years showed a worse response 
to inhaled steroids.
Clinical consequences
In discussing possible predictors of a long-term response 
to inhaled steroids, it has to be kept in mind that the 
studies referred to [22, 23] were not set up for this pur­
pose. For instance, in our study [22], which concerned 
a selective group of patients with COPD, all patients were 
selected on the basis that they had a decline in lung func­
tion of more than 80 mL^yr1, which made them less rep­
resentative of all patients with COPD or asthma. With 
this limitation in mind, there are indications that in 
COPD, the bronchodilating response at the start of ste­
roid treatment and the annual decline FEV1 in the pre­
ceding period appear to be predictors of the response to 
the inhaled steroid. Airways that respond only slightly to 
bronchodilators after a significant decline in lung func­
tion may have some degree of damage, such as loss of 
lung elastic recoil, hypertrophy of airway smooth muscle 
and thickening of the basement membrane, which may, 
in some instances, not be reversed either by broncho­
dilators or by corticosteroids [28, 29]. It is not only in 
long-term studies that the acute bronchodilating res­
ponse has been shown to be an important predictor of
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the long-term response to inhaled steroids. In short-term 
studies with systemic corticosteroids in patients with 
COPD, a significant relationship was also found between 
the bronchodilating response and the response to steroids 
[30-32],
It is possible that patients with the largest increase in 
airway obstruction during a period when no anti-inflam­
matory treatment is given, will demonstrate the largest 
improvements in FEVl during treatment with the inflam­
mation-reversing corticosteroids. Therefore, in patients 
with COPD, a large annual decline in FEVl in the ab­
sence of anti-inflammatory treatment is possibly a useful 
indication for additional treatment with inhaled cortico­
steroids. It is possible that in these patients smoking 
plays a less dominant role in the pathogenesis (or pro­
gression) of COPD. Current smoking and having a more 
severe smoking history appeared to be related to the 
response to inhaled steroids in patients with COPD [22, 
23]. This points to the relevance of the amount and dura­
tion of smoking to the long-term response to inhaled 
corticosteroids. More pack-years may be accompanied 
by more (irreversible) damage to the airways and a low­
er sensitivity to corticosteroids in COPD, A steroid res­
ponse in COPD seems to be lowest in subjects with a 
slow, irreversible deterioration in lung function, proba­
bly caused by long and heavy smoking. In patients with 
a rapidly progressive form of COPD, we hypothesize 
that treatment with inhaled corticosteroids is probably 
indicated because of the increased risk of early morbid­
ity and mortality in patients with a low lung function 
level and a high annual decline in lung function [33, 34], 
Large prospective studies in a wide range of patients 
with COPD are clearly warranted to test this hypothe­
sis. Data from large international studies, such as the 
Euroscop study, will become available in the near future
[35].
It has not yet been proved that COPD patients with 
typical asthmatic features have a better response to in­
haled corticosteroids. Apart from the reversibility, other 
features of asthma such as a high bronchial hyperre- 
sponsiveness and a high diurnal variation of the peak 
flow did not appear to be the most important determi­
nants of the response to inhaled corticosteroids in COPD 
[27]. Asthmatic features were predictors of the steroid 
response in the study of K erstjens et al. [26]. However, 
this might have been caused by the asthmatic subjects 
in their mixed study group [23]. Both bronchial hyper­
responsiveness {i.e. PC20 <8 mg-mL'1) and high diurnal 
variations of the peak flow (i.e. >15%) are important 
features of asthma [3, 36], which are very much related 
because they both express bronchial lability of the air­
ways of asthmatics [36], The degree of nonspecific bron­
chial responsiveness is closely related to the severity of 
inflammation in asthma [3], Therefore, it seems logical 
that asthmatic subjects with severe bronchial hyperresp­
onsiveness demonstrate the largest responses to inhaled 
corticosteroids.
It is possible that bronchial hyperresponsiveness in 
asthma is not the same as in COPD. J ames et al. [37] 
found no relationship between PC20 and response to cor­
ticosteroids in patients with COPD. It is possible that 
bronchial hyperresponsiveness in COPD does not signify 
inflammation as it does in asthma, but is rather an exp­
ression of the degree of existing airway obstruction [38,
39]. In none of the COPD studies could any influence 
of inhaled steroids on bronchial hyperresponsiveness 
(assessed by means of PC20) be observed [11-25]; whilst 
in all of the asthma studies, a significant reduction of 
bronchial hyperresponsiveness was shown [5-7, 21-23]. 
It seems probable that the inflammation in COPD is less 
responsive to inhaled corticosteroids than it is in asthma. 
This might be caused by the high steroid sensitivity of 
lymphocytes and eosinophils, which are found in relati­
vely high numbers in asthma but to a lesser extent in 
COPD in BAL studies [40],
In conclusion, use of inhaled steroids in chronic ob­
structive pulmonary disease seems to have some (in part 
dose-dependent) beneficial effects on lung function but 
not on bronchial hyperresponsiveness. Inhaled cortico­
steroids in chronic obstructive pulmonary disease may 
have some small effects on bronchial symptoms and exac­
erbations. There are indications that more reversibility 
of the airway obstruction and less smoking might be rela­
ted to a better long-term response to inhaled steroids in 
chronic obstructive pulmonary disease. However, before 
translating this to clinical practice, more data are urgent­
ly needed to support these observations. Long-term data 
with inhaled steroids in chronic obstructive pulmonary 
disease will soon become available.
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